# PhaseBio Pharmaceuticals
 (stock symbol: PHAS) Logo in transparent PNG format

## PhaseBio Pharmaceuticals
 Logo large

### PhaseBio Pharmaceuticals
 Logo large Download PNG (22.85 KB)

![PhaseBio Pharmaceuticals
 Logo large Download PNG (22.85 KB)](/img/orig/PHAS_BIG-27d7b16f.png)

## PhaseBio Pharmaceuticals
 Logo icon format

### PhaseBio Pharmaceuticals
 Logo icon format Download PNG (39.59 KB)

![PhaseBio Pharmaceuticals
 Logo icon format Download PNG (39.59 KB)](/img/orig/PHAS-0bac4567.png)

## About PhaseBio Pharmaceuticals


PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.

1. Website domain: phasebio.com
2. Employees: 60
3. Marketcap: $3.49 Million USD


## Categories
- [x] ðŸ‡ºðŸ‡¸ United States
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
